Skip to content

The Efficacity of Hemodiafiltration Versus Hemofiltration for Renal Insufficiency During Intensive Care

The Efficacity of Hemodiafiltration Versus Hemofiltration for Renal Insufficiency During Intensive Care: a Randomized, Open, Cross-over Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01403220
Enrollment
163
Registered
2011-07-27
Start date
2012-04-30
Completion date
2015-03-17
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Failure, Acute

Brief summary

The primary objective of this study is to compare the efficacity of hemodiafiltration and hemofiltration for decreasing plasma urea at 12h among intensive care patients. Secondary objectives include comparing urea clearance, filter duration, and %down-time, between the two techniques.

Interventions

PROCEDUREHemodiafiltration first

Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.

PROCEDUREHemofiltration first

Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* According to RIFLE score, patient is stage 'F' * The patient must be insured or beneficiary of a health insurance plan * The patient meets at least one of the following criteria: * metabolic acidosis (pH \< 7.2), excluding keto-acidosis * plasma urea \> 25 mmol/l * hyper-hydration is not controlled by diuretics

Exclusion criteria

* Chronic, terminal renal insufficiency with dialysis * The patient is under judicial protection, under tutorship or curatorship * Suspect hyperkaliemia (Kaliemia \> 6.5 mmol/l with electrocardiographic effects) * Intoxications treated via dialysis * Pregnant, lactating, parturient women * Medical indication for localized citrate anticoagulation * dialysis of less than 12 h * patient or representative refuses to participate

Design outcomes

Primary

MeasureTime frameDescription
Proportion of dialysis sequences for which the rate of plasma urea reduction > 60%.12 hoursProportion of dialysis sequences for which the rate of plasma urea reduction \> 60%. Rate of plasma urea reduction = (initial urea concentration - urea concentration after 12h our dialysis)/initial urea concentration.

Secondary

MeasureTime frameDescription
Proportion of dialysis sequences for which the rate of plasma urea reduction > 60%.24 hoursProportion of dialysis sequences for which the rate of plasma urea reduction \> 60%. Rate of plasma urea reduction = (initial urea concentration - urea concentration after 12h our dialysis)/initial urea concentration.
Urea clearance (ml/min) for the dialysis sequence under study12 hoursUrea clearance (ml/min) for the dialysis sequence under study.
Filter lifespan (hours) for the dialysis sequence under study.12 hours.Filter lifespan (hours) for the dialysis sequence under study.
The percentage down-time for the first 24 hours of dialysis24 hoursThe percentage down-time for the first 24 hours of dialysis = (number of hours where the exchange is not effective / 24 hours)\*100
Fluid replacement (yes/no)12 hoursWas fluid replacement necessary during the studied dialysis sequence?

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026